• Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. 

  Poudel, P; Nyamundanda, G; Patil, Y; Cheang, MCU; Sadanandam, A

  Breast cancer is a highly heterogeneous disease. Although differences between intrinsic breast cancer subtypes have been well studied, heterogeneity within each subtype, especially luminal-A cancers, requires further ...
• ISBN 978-3-030-11391-9 

  Else, M; Catovsky, D (Springer, 2019-03-01)
• Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials 

  Wojdacz, TK; Amarasinghe, HE; Kadalayil, L; Beattie, A; Forster, J; Blakemore, SJ; Parker, H; Bryant, D; Larrayoz, M; Clifford, R; Robbe, P; Davis, ZA; Else, M; Howard, DR; Stamatopoulos, B; Steele, AJ; Rosenquist, R; Collins, A; Pettitt, AR; Hillmen, P; Plass, C; Schuh, A; Catovsky, D; Oscier, DG; Rose-Zerilli, MJJ; Oakes, CC; Strefford, JC (American Society of Hematology, 2019-08-27)

  <jats:title>Key Points</jats:title> <jats:p>DNA methylation signatures can be used to divide IGHV-mutated CLL into clinically relevant subgroups. The memory-like DNA methylation subgroup is an independent marker of prolonged ...
• Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model. 

  Richartz, N; Duthil, E; Ford, A; Naderi, EH; Bhagwat, S; Gilljam, KM; Burman, MM; Ruud, E; Blomhoff, HK; Skah, S (2019-11-12)

  Acute lymphoblastic leukemia (ALL) develops in the bone marrow in the vicinity of stromal cells known to promote tumor development and treatment resistance. We previously showed that the cyclooxygenase (COX) inhibitor ...
• The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukaemia: Challenges for Diagnosis and Therapy. 

  Grobbelaar, C; Ford, AM

  Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Although the overall survival of children with ALL is now more than 90%, leukaemia remains one of the leading causes of death from disease. In ...
• Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. 

  Bisogno, G; De Salvo, GL; Bergeron, C; Gallego Melcón, S; Merks, JH; Kelsey, A; Martelli, H; Minard-Colin, V; Orbach, D; Glosli, H; Chisholm, J; Casanova, M; Zanetti, I; Devalck, C; Ben-Arush, M; Mudry, P; Ferman, S; Jenney, M; Ferrari, A; European paediatric Soft tissue sarcoma Study Group (2019-11)

  BACKGROUND: For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether ...
• Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer 

  von Loga, K; Woolston, A; Punta, M; Barber, L; Griffiths, B; Semiannikova, M; Spain, G; Challoner, B; Fenwick, K; Simon, R; Marx, A; Sauter, G; Lise, S; Matthews, N; Gerlinger, M
• Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. 

  Clarke, NW; Ali, A; Ingleby, FC; Hoyle, A; Amos, CL; Attard, G; Brawley, CD; Calvert, J; Chowdhury, S; Cook, A; Cross, W; Dearnaley, DP; Douis, H; Gilbert, D; Gillessen, S; Jones, RJ; Langley, RE; MacNair, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Parker, CC; Ritchie, AWS; Rush, H; Russell, JM; Brown, J; Beesley, S; Birtle, A; Capaldi, L; Gale, J; Gibbs, S; Lydon, A; Nikapota, A; Omlin, A; O'Sullivan, JM; Parikh, O; Protheroe, A; Rudman, S; Srihari, NN; Simms, M; Tanguay, JS; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A; Sydes, MR; Parmar, MKB; James, ND (2019-09-27)

  BACKGROUND: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report ...
• Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study. 

  Barrow-McGee, R; Procter, J; Owen, J; Woodman, N; Lombardelli, C; Kothari, A; Kovacs, T; Douek, M; George, S; Barry, PA; Ramsey, K; Gibson, A; Buus, R; Holgersen, E; Natrajan, R; Haider, S; Shattock, MJ; Gillett, C; Tutt, AN; Pinder, SE; Naidoo, K (2019-11-22)

  Understanding how breast cancer (BC) grows in axillary lymph nodes (ALNs), and refining how therapies might halt that process, is clinically important. However, modelling the complex ALN microenvironment is difficult, and ...
• Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. 

  Martinez, VG; Pankova, V; Krasny, L; Singh, T; Makris, S; White, IJ; Benjamin, AC; Dertschnig, S; Horsnell, HL; Kriston-Vizi, J; Burden, JJ; Huang, PH; Tape, CJ; Acton, SE (2019-11-26)

  Lymph nodes (LNs) act as filters, constantly sampling peripheral cues. This is facilitated by the conduit network, a tubular structure of aligned extracellular matrix (ECM) fibrils ensheathed by fibroblastic reticular cells ...
• Proteomic research in sarcomas - current status and future opportunities. 

  Burns, J; Wilding, CP; L Jones, R; H Huang, P (2019-11-10)

  Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains ...
• Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. 

  Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; Waterhouse, A; Jones, JR; Kishore, B; Garg, M; Williams, CD; Karunanithi, K; Lindsay, J; Wilson, JN; Jenner, MW; Cook, G; Kaiser, MF; Drayson, MT; Owen, RG; Russell, NH; Gregory, WM; Morgan, GJ; UK NCRI Haematological Oncology Clinical Studies Group (2019-12)

  BACKGROUND: Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents ...
• Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. 

  Pancholi, S; Leal, MF; Ribas, R; Simigdala, N; Schuster, E; Chateau-Joubert, S; Zabaglo, L; Hills, M; Dodson, A; Gao, Q; Johnston, SR; Dowsett, M; Cosulich, SC; Maragoni, E; Martin, L-A (2019-12-04)

  BACKGROUND: Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been ...
• A translational study in pancreatic neuroendocrine neoplasms 

  Young, K (2019-11-30)

  Pancreatic neuroendocrine neoplasms (PanNENs) are rare, highly heterogeneous tumours. There have been significant recent advances in our knowledge of genomic events underlying their pathogenesis. However, treatment decisions ...
• Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. 

  Pietrantonio, F; Miceli, R; Raimondi, A; Kim, YW; Kang, WK; Langley, RE; Choi, YY; Kim, K-M; Nankivell, MG; Morano, F; Wotherspoon, A; Valeri, N; Kook, M-C; An, JY; Grabsch, HI; Fucà, G; Noh, SH; Sohn, TS; Kim, S; Di Bartolomeo, M; Cunningham, D; Lee, J; Cheong, J-H; Smyth, EC (2019-12-10)

  PURPOSE: In the CLASSIC and MAGIC trials, microsatellite instability (MSI)-high status was a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant chemotherapy in resectable gastric cancer ...
• Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. 

  Newey, A; Griffiths, B; Michaux, J; Pak, HS; Stevenson, BJ; Woolston, A; Semiannikova, M; Spain, G; Barber, LJ; Matthews, N; Rao, S; Watkins, D; Chau, I; Coukos, G; Racle, J; Gfeller, D; Starling, N; Cunningham, D; Bassani-Sternberg, M; Gerlinger, M (2019-11-18)

  BACKGROUND: Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics ...
• Class(y) Dissection of BRAF Heterogeneity: Beyond Non-V600. 

  Fontana, E; Valeri, N (2019-12-01)

  Different classes of BRAF mutations are present in colorectal and other cancers. Non-V600 mutations are rare; however, their detection rate will increase as the use of next-generation sequencing ramps up quickly in clinical ...
• Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients 

  Dowsett, M; Gao, Q; Martin, L-A; Lopez-Knowles, E; Ribas, R
• Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: a TransATAC study. 

  Buus, R; Sestak, I; Barron, S; Loughman, T; Fender, B; Ruiz, CL; Dynoodt, P; Wang, C-JA; O'Leary, D; Gallagher, WM; Dowsett, M; Cuzick, J (2019-10-22)

  PURPOSE: To test the validity of OncoMasTR Molecular Score (OMm), OMclin1 and OncoMasTR Risk Score (OMclin2) prognostic scores for prediction of distant recurrence (DR) in ER-positive/HER2-negative breast cancer treated ...
• The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. 

  Wilding, CP; Elms, ML; Judson, I; Tan, A-C; Jones, RL; Huang, PH (2019-11)

  Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ...

View more